» Articles » PMID: 18664318

Management of Peripheral Arterial Disease Patients: Comparing the ACC/AHA and TASC-II Guidelines

Overview
Publisher Informa Healthcare
Date 2008 Jul 31
PMID 18664318
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis associated with a high risk of morbidity and mortality from cardiovascular events. Despite this, PAD is often undiagnosed and, therefore, undertreated.

Objective: The purpose of this review is to highlight and provide clinical insight into the similarities and differences between the available PAD treatment guidelines developed by the American College of Cardiology/American Heart Association (ACC/AHA) and the Trans-Atlantic Inter-Society Consensus II (TASC II) working group.

Methods: Recommendations from the ACC/AHA 2005 Practice Guidelines for the Management of Patients with Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) and TASC II Inter-Society Consensus for the Management of Peripheral Arterial users for personal Disease, initiated in 2004 and published in 2007, were compared. Supplemental information was obtained by searching the PubMed and MEDLINE databases using relevant terms. Unintentional bias may have been introduced into the manuscript by not performing a systematic review of the literature with pre-defined search terms.

Findings And Conclusions: While some variation exists in the content of the recommendations, both documents agree on the need for aggressive management of patients with PAD. In spite of these recommendations, there is a general lack of adherence to the current guidelines-a critical concern considering the high morbidity and mortality associated with the disease. However, the results of ongoing clinical trials may serve to increase awareness of the importance of aggressive management of PAD.

Citing Articles

Transcatheter arterialization of the deep veins: 1-year outcomes of PROMISE-UK study.

Zayed H, Saratzis A, Moxey P, Rashid S, Mezes P, Diamantopoulos A Br J Surg. 2024; 111(7).

PMID: 39078986 PMC: 11288327. DOI: 10.1093/bjs/znae188.


Popliteal access for endovascular procedures in femoropopliteal artery occlusive disease.

Yilmaz S, Kiziltan F, Kalender M, Parlar H, Saskin H, Baris O Postepy Kardiol Interwencyjnej. 2023; 19(3):277-283.

PMID: 37854961 PMC: 10580849. DOI: 10.5114/aic.2023.131482.


Polymer Free Amphilimus Drug Eluting Stent for Infrapopliteal Arterial Disease in Patients with Critical Limb Ischemia: A New Device in the Armamentarium.

Tigkiropoulos K, Abatzis-Papadopoulos M, Sidiropoulou K, Stavridis K, Karamanos D, Lazaridis I Medicina (Kaunas). 2023; 59(1).

PMID: 36676663 PMC: 9866247. DOI: 10.3390/medicina59010039.


One-year outcomes following primary stenting of infrapopliteal steno-occlusive arterial disease using a non-polymer sirolimus-eluting stent: Results from a prospective single-centre cohort study.

Tigkiropoulos K, Lazaridis I, Nikas S, Abatzis-Papadopoulos M, Sidiropoulou K, Stavridis K Front Surg. 2022; 9:955211.

PMID: 36277289 PMC: 9581304. DOI: 10.3389/fsurg.2022.955211.


A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.

Gu Y, Cui S, Wang Q, Liu C, Jin B, Guo W Mol Ther. 2019; 27(12):2158-2165.

PMID: 31805256 PMC: 6904746. DOI: 10.1016/j.ymthe.2019.10.017.